Dmitrij Hristodorov, partner at Forbion, told the Sachs Forum audience there were clear signs of a comeback for the cardiovascular/cardiometabolic (CVM) market. He highlighted new drug approvals in dyslipidemia , hypertension, diabetes, obesity and cardiomyopathy as key indications that there is more to come in the CVM space in the coming few years. The panelists discussed historic and new challenges in the market, regulatory rigor, and the availability of different modalities to treat CVM diseases.
According to recent data, clinical-stage cardiometabolic assets account for around 7% of the overall industry R&D pipeline. The top 5...
